/BCX.WA
BCX.WA Stock - Bioceltix S.A.
Healthcare|BiotechnologyWSE
$80.00-1.60%
$1.30 (-1.60%) • Dec 23
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $88.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCX.WA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$79.20 – $80.80
TARGET (TP)$92.00
STOP LOSS$73.60
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$129.00
52W Low$73.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $10,800 |
| Gross Profit | $-574,435 | $-1,038,075.9 | $-445,385 | $-376,978 | $-3,867,080 |
| Gross Margin | N/A | N/A | N/A | N/A | -35806.3% |
| Operating Income | $-18,829,934 | $-15,819,560 | $-9,672,870 | $-6,213,550 | $-3,988,940 |
| Net Income | $-14,897,938 | $-13,687,545 | $-8,921,382 | $-4,397,615 | $-2,348,754 |
| Net Margin | N/A | N/A | N/A | N/A | -21747.7% |
| EPS | $-3.28 | $-3.49 | $-2.67 | $-1.39 | $-0.95 |
Company Overview
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BCX.WABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.89
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 28, 2025 | — | $-0.89 | — | — |
Q2 2025 | May 29, 2025 | — | $-0.77 | — | — |
Q2 2025 | Apr 28, 2025 | — | $-0.61 | — | — |
Q4 2024 | Oct 18, 2024 | — | $-0.78 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-1.02 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-1.02 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.91 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.92 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.99 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.74 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.82 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.85 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.57 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.44 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.48 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.33 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BCX.WA
What is BCX.WA's current stock price?
Bioceltix S.A. (BCX.WA) is currently trading at $80.00 per share. The stock has moved -1.60% today.
What is the analyst price target for BCX.WA?
No analyst price targets are currently available for this stock.
What sector is Bioceltix S.A. in?
Bioceltix S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the WSE exchange.
What is BCX.WA's market cap?
Bioceltix S.A. has a market capitalization of $0.39 billion, making it a small-cap company.
Does BCX.WA pay dividends?
No, Bioceltix S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIO.WA
Bioton S.a.
$3.76
Mkt Cap: $0.3B
CTX.WA
Captor Therapeutics Spolka Akcyjna
$69.80
Mkt Cap: $0.4B
ENE.WA
Centrum Medyczne ENEL-MED S.A.
$18.00
Mkt Cap: $0.5B
MAB.WA
Mabion S.A.
$6.95
Mkt Cap: $0.1B
MDG.WA
Medicalgorithmics S.A.
$34.00
Mkt Cap: $0.3B
MRC.WA
Mercator Medical S.A.
$37.45
Mkt Cap: $0.3B
PTG.WA
Poltreg S.A.
$24.60
Mkt Cap: $0.1B
RVU.WA
Ryvu Therapeutics S.A.
$25.35
Mkt Cap: $0.6B
SCP.WA
Scope Fluidics S.A.
$143.40
Mkt Cap: $0.4B
SVE.WA
Synthaverse S.A.
$3.53
Mkt Cap: $0.2B
Explore stocks similar to BCX.WA for comparison